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Folate Receptor Alpha Defect Causes Cerebral Folate
Transport Deficiency: A Treatable Neurodegenerative
Disorder Associated with Disturbed Myelin Metabolism
Robert Steinfeld,1,5,* Marcel Grapp,1,5 Ralph Kraetzner,1 Stefﬁ Dreha-Kulaczewski,1 Gunther Helms,2
Peter Dechent,2 Ron Wevers,3 Salvatore Grosso,4 and Jutta Ga¨rtner1
Sufﬁcient folate supplementation is essential for a multitude of biological processes and diverse organ systems. At least ﬁve distinct in-
herited disorders of folate transport and metabolism are presently known, all of which cause systemic folate deﬁciency. We identiﬁed an
inherited brain-speciﬁc folate transport defect that is caused by mutations in the folate receptor 1 (FOLR1) gene coding for folate receptor
alpha (FRa). Three patients carrying FOLR1mutations developed progressivemovement disturbance, psychomotor decline, and epilepsy
and showed severely reduced folate concentrations in the cerebrospinal ﬂuid (CSF). Brain magnetic resonance imaging (MRI) demon-
strated profound hypomyelination, and MR-based in vivo metabolite analysis indicated a combined depletion of white-matter choline
and inositol. Retroviral transfection of patient cells with either FRa or FRb could rescue folate binding. Furthermore, CSF folate concen-
trations, as well as glial choline and inositol depletion, were restored by folinic acid therapy and preceded clinical improvements. Our
studies not only characterize a previously unknown and treatable disorder of early childhood, but also provide new insights into the
folate metabolic pathways involved in postnatal myelination and brain development.Introduction
Folates are essential cofactors for one-carbon methyl trans-
fer reactions and are crucial for a variety of biological
processes, such as synthesis and repair of DNA,1–3 regula-
tion of gene expression,4,5 and synthesis of amino acids
and neurotransmitters.6,7 Folate deﬁciency is one of the
major dietary health problems worldwide.8 Humans
require 400–600 mg of dietary folate per day, and children
and adolescents are the population at the greatest risk of
suffering nutritional folate deﬁciency. Dietary folate is
taken up in the gut, metabolized in the liver to 5-methyl-
tetrahydrofolate (MTHF), then distributed by the blood-
stream. Cellular uptake of MTHF is mediated by the
proton-coupled folate transporter (PCFT; SLC46A1 [MIM
*611672]), the reduced folate carrier (RFC; SLC19A1 [MIM
*600424]), and by two GPI-anchored receptors, folate
receptor alpha (FRa [MIM *136430]) and beta (FRb [MIM
*136425]).9 FRa is distributed mainly at epithelial cells,
such as choroid plexus, lung, thyroid, and renal tubular
cells, whereas FRb is located mainly within mesenchymal
derived cells, such as red blood cells. Both are high-afﬁnity
receptors that function at the physiological nanomolar
range of extracellular folate concentrations. RFC is ubiqui-
tously distributed and represents a low-afﬁnity folate-
transporting system with bidirectional transport across
membranes.10 PCFT is highly expressed in the small intes-
tine, where folates are absorbed at low pH in the microcli-
mate of the intestinal epithelium. However, PCFT is also
expressed in many other tissues, including the brain,354 The American Journal of Human Genetics 85, 354–363, Septemwhere it might export folates from acidiﬁed endosomes
after FRa-mediated endocytosis.11 At least ﬁve distinct in-
herited disorders of folate transport and metabolism are
presently known, all of which lead to generalized folate
deﬁciency.12–17 Besides these inherited disorders, an auto-
immune folate deﬁciency with a variable clinical pheno-
type has also been described.18
To our knowledge, we describe here the ﬁrst inherited
disorder of brain-speciﬁc folate deﬁciency. Loss-of-func-
tion mutations in the FOLR1 gene (MIM *136430) coding
for the FRa predominantly impairs cerebral folate trans-
port. This autosomal-recessive disorder manifests in late
infancy with severe developmental regression, movement
disturbances, epilepsy, and leukodystrophy. Folinic acid
therapy can reverse the clinical symptoms and improve
brain abnormalities and function.
Subjects and Methods
Subjects
Two siblings of healthy, unrelated German parents, patients 1 and
2, had an uneventful medical history and were found to be
compound heterozygous for two nonsense mutations in the
FOLR1 gene coding for FRa. At the time of diagnosis, at the age
of 3 years and 19months, the older boy was severely handicapped,
wheel-chair bound, and suffered from therapy-resistant epileptic
seizures. Oral folinic acid treatment was started. Since then, the
frequency and severity of epileptic seizures have declined and
the boy has started to walk with support. His sister, younger by
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her ﬁrst motor symptoms, at the age of 2 years and 3 months. She
completely recovered and has not developed clinical symptoms
since then. Patient 3, carrying a homozygous duplication in the
FOLR1 gene, is the daughter of healthy parents who originate
from a small Italian village. At the age of 5 years, she was severely
handicapped, mentally retarded, and suffered from frequent epi-
leptic seizures, at which point she was diagnosed as having cere-
bral folate transport deﬁciency and folate treatment was started.
Her clinical condition has also slowly improved since then. The
institutional ethics committee approved the described investiga-
tions, and the parents gave informed consent before each exami-
nation.
Measurements of Cerebrospinal Fluid Metabolites
MTHF in cerebrospinal ﬂuid (CSF) was measured with high-perfor-
mance liquid chromatography (HPLC), with ﬂuorimetric detec-
tion essentially as described before.19 In all three patients, analysis
of CSF disclosed a very lowMTHF concentration of below 5 nmol/L.
The MTHF concentration in CSF increased during folinic acid
treatment. In patient 1, it was 1.4 nmol/L before the start of
therapy and 41 nmol/L on treatment with 5 mg folinic acid/kg/
day. On 3.5 mg folinic acid/kg/day, CSF folate was 53 nmol/L in
patient 2 at the age of 2.5 yrs. Reference values for CSF folate in
the age group of 2–5 years amount to: median 74 nmol/L, range
min–max 43–159, in 35 controls.19 Normal concentrations were
found in CSF for total protein, glucose, amino acids, and the
neurotransmitter metabolites HVA, MHPG 5HIAA, and methyl-
malonic acid before the start of therapy. Myo-inositol in
CSF was determined with gas chromatography mass spectrometry
(GC-MS) essentially as according to Jansen.20 Before the start of
therapy, in patient 1 myo-inositol in CSF amounted to
160 mmol/L, whereas a concentration of 143 mmol/L was found
on treatment of 5 mg folinic acid/kg/day (range in ten age-
matched disease-affected controls not on folate or folinic acid
therapy: 117–252; age range 0.8–5.5 years). In patient 2, the CSF
myo-inositol was normal under folinic acid supplementation
(238 mmol/L).
DNA Sequencing
For ampliﬁcation and sequencing of genomic DNA fragments
of FRa, the primer combinations hFOLR1gDNA6206F (50-GGGC
TGGGGAATCAAGGACTAAGAGG-30) and hFOLR1gDNA6611R
(50-CCAGCAACTCAGCCCCGAATAGAACT-30) for exon 3 and
hFOLR1gDNA6863F (50-AATTTGGAGTTGTAGGGCTGGCAGAC-30)
and hFOLR1gDNA7404R (50-GGGAATTGGAAAACAAAACAGTC
ACG-30) for exon 5 were used. The BigDye Terminator Kit was
used for semiautomated sequencing, in accordance with the
recommendations of the manufacturer (Perking Elmer Applied
Biosystems).
Semiquantitative RT-PCR
RNA was isolated from patient ﬁbroblasts and lymphocytes with
the RNeasy Kit as described by the manufacturer (QIAGEN). For
cDNA synthesis, the Superscript III First-Strand Synthesis System
(Invitrogen) was used. Reverse transcriptase-polymerase chain
reaction (RT-PCR) was used for analysis of the mRNA abundance
of FRa and FRb in cultured ﬁbroblasts and leukozytes from patients
and controls, respectively, and in CHO-K1 cells stably expressing
wild-type (WT) or mutant FRa. Total mRNA was prepared and
reverse transcription was done with the use of a cDNA Synthesis
Kit (Invitrogen). Speciﬁc primer pairs are given in Table S1 (avail-The Americanable online) and were used with 2 ml of cDNA. PCR ampliﬁcation
was carried out with 37 cycles and 59C annealing temperature.
RT-PCR products were analyzed by agarose gel electrophoresis
and compared against GAPDH.
Folate Binding
Patient ﬁbroblasts or stably transfected CHO-K1 cells in 6-well
plates were washed with acid buffer, equilibrated to neutral HEPES
buffer, then exposed to 5 nmol/L [3H]folate or 5 nmol/L [3H]folate
þ 110 nmol/L methotrexate for 15 min. [3H]folate bound to the
cell surface was released with acid buffer and measured on a liquid
scintillation counter. Speciﬁc folate binding was calculated from
the difference between [3H]folate bound in the presence and
absence of 500 nmol/L nonlabeled folate. [30,50,70,9-3H]Folate
was obtained fromMoravek Biochemicals (Brea, CA, USA). Patient
ﬁbroblasts or stably transfected CHO-K1 cells were seeded in
6-well plates 24 hr before the binding assay. Cells were washed
with ice-cold acid buffer (10 mmol/L NaAc, 150 mmol/L NaCl
[pH 3.5]). After a washing step with ice-cold HEPES-buffered saline
(HBS) (20 mmol/L HEPES, 140 mmol/L NaCl, 5 mmol/L KCl,
2 mmol/L MgCl2, 5 mmol/L glucose [pH 7.4]), cells were exposed
to 5 nmol/L [3H]folate or 5 nmol/L [3H]folateþ 110 nmol/L meth-
otrexate for 15 min in ice-cold HBS. At this concentration, meth-
otrexate selectively inhibits folate binding to the RFC but does not
affect FRa-related binding. Also, at neutral pH, folate does not bind
to the proton-coupled folate transporter (PCFT). Cells were then
washed three times with [3H]folate-free HBS. [3H]folate bound to
the cell surface was released with acid buffer (1 mL) and measured
on a liquid scintillation spectrometer. Speciﬁc folate binding was
calculated from the difference between [3H]folate bound in the
presence and absence of 500 nmol/L nonlabeled folate. The
adherent cells were subsequently lysed, and protein was deter-
mined with the use of the BCA Protein Kit (Pierce, Rockford, IL).
All experiments were repeated at least three times and gave very
similar results.
Retrovirus Infection
Human FRa and FRb cDNA were introduced into the vector
pLNCX2 (Clontech). The plasmids were transfected into the pack-
aging cells, Retro Pack PT67 (Clontech), and the culture superna-
tant was ﬁltered and added onto the patient ﬁbroblasts. Folate
binding studies were carried out as described above.
Expression of WT and Mutant FRa in CHO-K1 Cells
FRa cDNA was cloned into the expression vector pcDNA3.1(-) (In-
vitrogen). Mutant FRa[p.K44_P49 dup] was obtained by primerless
PCR.21 Chinese hamster ovary (CHO) cells were either transiently
or stably transfected with WT and mutant FRa and then assayed
for folate-binding capacity either directly or after 14 days of selec-
tion with G418. The folate-binding assay was performed as
described above.
Immunoblot Analysis of FRa Expression
Stable CHO-K1 clones expressing WT or mutant FRa were col-
lected in CellLytic M Cell Lysis Reagent (Sigma), and lysates
were subjected to SDS-PAGE (12% gel) under nonreducing condi-
tions and transferred to a nitrocellulose membrane. The mem-
brane was probed with a monoclonal anti-human FRa antibody
(Mov18, ALEXIS Biochemicals).Journal of Human Genetics 85, 354–363, September 11, 2009 355
Figure 1. FOLR1 Mutations Cause Deficient Folate Binding to FRa
Sequencing of the FOLR1 gene coding for FRa disclosed two nonsense mutations, p.Q118X and p.C175X, in patient 1 and his younger
sister, patient 2 (A). Compound heterozygosity was proven by the presence of both mutant alleles in either the maternal or the paternal
DNA. Analysis of genomic DNA (and cDNA, not shown) of patient 3 revealed a homozygous duplication, p.K44_P49dup, in the FOLR1
gene, which caused an insertion of the amino acid sequence ‘‘KEKPGP’’ without change of the reading frame. Sequencing of the parents’
DNA showed that the father and mother are heterozygous carriers of the duplication p.K44_P49dup. Semiquantitative RT-PCR with
cDNA from all three patients (B) showed an almost normal transcript size for patient 3 carrying the duplication p.K44_P49dup but hardly
any transcript for the two siblings with the nonsense mutations. Instead, the ampliﬁed fragment size corresponds to the product of the356 The American Journal of Human Genetics 85, 354–363, September 11, 2009
Immunoﬂuorescent Microscopy
CHO-K1 cells stably expressing WTor mutant FRa were permeabi-
lized and blocked with 5 mg/ml saponin in PBS for 1 hr at room
temperature and subsequently incubated with mouse monoclonal
anti-human FRa (Mov18, 1:100 dilution) and rabbit polyclonal
anti-calreticulin (1:50 dilution) in PBS containing 1 mg/ml sapo-
nin. After three washes with PBS, cells were incubated with the
appropriate secondary antibodies conjugated with Alexa Fluor
488 or 546 for 1 hr in the dark. Coverslips were mounted and
viewed with a Leica NTSC laser confocal microscope in sequential
scanmode. At least 50 cells per coverslip were examined under the
microscope, and representative cells were photographed.
Magnetic Resonance Imaging and Proton Magnetic
Resonance Spectroscopy
Brain magnetic resonance imaging (MRI) was performed with
either a 1.5 Tesla or a 3 Tesla scanner. The two siblings, patients
1 and 2, underwent localized protonmagnetic resonance spectros-
copy (MRS) studies at 3 Tesla (Magnetom Trio, Siemens Health-
care) before and after the onset of folinic acid treatment. Fully
relaxed MR spectra were acquired with the use of the STEAM
sequence as described previously.22 Metabolites, quantiﬁed by
LCModel23 and compared to age-matched controls, include the
neuroaxonal marker N-acetylaspartate and N-acetylaspartylgluta-
mate (tNAA), creatine and phosphocreatine (tCr) as compounds
linked to energy metabolism, choline-containing compounds
(Cho) involved in membrane turnover, and the glial marker
myo-inositol (Ins).24 The third patient had already received folate
therapy when we included her in the study and therefore no
proton MRS was performed.
Real-Time PCR for Quantiﬁcation of Human Folate
Transporter Expressions
For real-time PCR analysis, human cDNAwas purchased from Bio-
Chain (Hayward, CA). Real-time PCR was used for verifying the
expression levels of FRa, FRb, FRg, RFC, and PCFT in different
tissues with the use of the iQ SYBR Green ﬂuorescent intercalation
dye (Bio-Rad Laboratories, Hercules, CA). For each gene, primer
pairs were designed (Table S1), covering exon boundaries so that
ampliﬁcation of genomic DNA was avoided. The PCR reactions
were performed in a ﬁnal volume of 15 ml, with the use of 7,5 ml
of iQ SYBR Green Supermix (Bio-Rad Laboratories), 3 pmol of
each primer, and 0,25 ng of cDNA. Before ampliﬁcation, an initial
denaturation step at 98C was performed, ensuring activation of
the polymerase and complete denaturation of the cDNA. All
PCR reactions were performed with 40 cycles and 59C annealing
temperature for FRa, FRb, FRg, and RFC or 63C for PCFT. Ampli-
ﬁed products underwent melting curve analysis after the last cycle
for specifying the integrity of ampliﬁcation. All runs included
a negative cDNA control consisting of PCR-grade water, and
each sample wasmeasured in triplicate. ThemRNAvalues were ex-
pressed relative to the housekeeping gene GAPDH and calculated
as n-fold expression relative to that.The AmericanResults
We have screened 12 patients with low MTHF concentra-
tions in the CSF and normal MTHF blood levels for folate
transporter defects and found three children with patho-
genic mutations in the FOLR1 gene. All three children
experienced the onset of symptoms beyond the second
year of life. Analysis of genomic DNA from two siblings
(patients 1 and 2) revealed two compound-heterozygous
nonsense mutations, p.Q118X and p.C175X, in FOLR1
(Figure 1A). In a third patient (patient 3), we identiﬁed
a homozygous in-frame duplication, p.K44_P49dup, in
FOLR1. All three FOLR1 mutations have been deposited
to the NCBI dbSNP (see Web Resources). Semiquantitative
PCR analysis on patient cDNA showed an apparently
normal transcript length in the case of the duplication
but no transcript for the nonsense mutations (Figure 1B).
Binding studies demonstrated a loss of FR-speciﬁc folate
binding to patient ﬁbroblasts (Figure 1C). Folate binding
could be rescued by retroviral transfection of ﬁbroblasts
with WT FRa. Interestingly, introduction of WT FRb that
is not expressed in ﬁbroblasts could also restore FR-speciﬁc
binding in patient ﬁbroblasts. No pathogenic mutations
were detected in the genes coding for other folate trans-
porters, and the presence of autoantibodies against the
folate receptors in serum was excluded. DNA analyses of
105 controls (210 alleles) revealed none of the three muta-
tions in the FOLR1 gene (data not shown).
Duplicationp.K44_P49dup in the FOLR1 gene leads to an
almost complete loss of FRa function. We disclosed the
molecularmechanismof reduced folate binding byheterol-
ogous expression of WT and p.K44_P49dup FRa in CHO
cells (Figures 2A–2D). AlthoughWTandmutant transcripts
were similar in intensity, transfection ofWT FRa resulted in
a 20-fold increase of folate binding but p.K44_P49dup FRa
in only a 3-fold increase. Immunoblot analysis revealed
that expression of mutant FRa was severely reduced in
comparison to WT FRa (Figure 2C). In addition, most of
mutant FRa was not localized at the plasma membrane
butmistargeted to intracellular compartments when inves-
tigated by immunoﬂuorescence microscopy (Figure 2D).
In case of patients 1 and 3, therapy with folinic acid, a
5-formyl derivative of tetrahydrofolate, was delayed by
several years after the onset of the ﬁrst clinical symptoms,
at a timewhenboth alreadyhad seriousmotor dysfunction,
developmental regression, and epileptic seizures. Brain
MRI showed a severely disturbed myelination affecting
the periventricular and the subcortical white matter when
compared to age-matched controls (Figures 3A–3C). In
contrast, patient 2, the younger sister of patient 1, wascontaminating genomic DNA, suggesting that the two premature termination codons lead to premature mRNA decay. Speciﬁc binding
of [3H]folate to patient ﬁbroblasts was determined in the presence or absence of 110 nmol/L methotrexate (C). At this concentration,
methotrexate selectively inhibits folate binding to the reduced folate carrier (RFC) but does not affect FRa-related binding. Patient ﬁbro-
blasts showed almost complete loss of methotrexate-independent folate binding (shown in ﬁbroblasts of patients 1 and 3). Retroviral
introduction ofWT FRa or FRb into patient ﬁbroblasts (shown only for patient 1) restored and overcompensated methotrexate-indepen-
dent folate binding. Note that FRb is not naturally expressed in human ﬁbroblasts and that neutral pH assay conditions exclude PCFT-
related binding.Journal of Human Genetics 85, 354–363, September 11, 2009 357
Figure 2. Mutant FRa Containing the KEKPGP Duplication is Instable and Mistargeted
Heterologous stable protein expression of the duplicationmutant p.K44_P49dup in CHO-K1 cells demonstrated only aminor increase in
folate binding and small amounts of protein expression for the duplication mutant when compared to WT FRa, albeit both transcripts
were similar in intensity (A–C). In confocal immunoﬂuorescence microscopy, mutant protein with the duplication p.K44_P49dup was
not detected at the cell membrane butmistargeted to intracellular compartments that partially colocalize with the ERmarker calreticulin
(D). Hence, thismutation is likely to causemajormisfolding and subsequent premature degradation of themutant protein. The length of
the displayed white bar corresponds to 20 mm.treated with folinic acid when the ﬁrst signs of movement
disturbances appeared. She demonstrated similar but
milder MR abnormalities. In all three patients, analysis
of the cerebrospinal ﬂuid (CSF) disclosed very low
MTHF concentrations but gave normal concentrations
for total protein, glucose, amino acids, neurotransmit-
ters, and myo-inositol. MTHF, cobalamin, and amino
acid concentrations in plasma and MTHF concentration
in erythrocytes showed no abnormalities (for details,
see Measurements of Cerebrospinal Fluid Metabolites).
In vivo proton MRS revealed abnormal concentrations
of brain metabolites and, most strikingly, reduced
choline and inositol peaks in the parieto-occipital white
matter (Figure 3D). In the gray matter, choline and myo-
inositol content were within the lower normal range,
and the N-acetylaspartate signal was slightly decreased
(Figure S1, available online). Supplementation with fo-
linic acid led to clinical improvement in patients 1358 The American Journal of Human Genetics 85, 354–363, Septemand 3 but resulted in immediate complete recovery in
patient 2. After 6 months of treatment, the white-matter
choline and inositol signals were normalized (Figure 3E)
and the ﬁrst signs of remyelination were visible on
brain MRI.
To assess the relative contribution of different folate
transporters in the human brain and major organs, we
compared the tissue-speciﬁc mRNA expression of FRa,
FRb, FRg (MIM *602469), PCFT, and RFC (Figure 4). In
the choroid plexus, FRa is highly expressed and highest
among all folate transporters. In contrast, FRb and PCFT
expressions are lower in the choroid plexus but signiﬁ-
cantly higher in other brain regions in comparison to
FRa expression. No signiﬁcant FRg or RFC expression is de-
tected in the choroid plexus. Thus, we conclude that FRa is
the major human folate transporter across the blood-CSF
barrier and is most crucial for cerebral folate supply. Inter-
estingly, FRb expression is particularly high in the humanber 11, 2009
Figure 3. Brain Imaging in Patients with Cerebral Folate Transport Deficiency
Sagittal T2-weighted MRI of patient 1 at the age of 4 years (A) reveals severely impaired myelination of the white matter and brain
atrophy when compared to an age-matched control (B). Brain metabolites were determined by in vivo magnetic resonance spectroscopy
(MRS); here is shown the spectrum for a volume of interest (black square in A) in the parieto-occipital white matter. Patient 1 shows
strongly decreased signals for choline andmyo-inositol in the parieto-occipital whitematter (C) in comparison to an age-mached control
(D). Six months after the beginning of folinic acid therapy choline and myo-inositol signals are normalized (E). Abbreviations corre-
spond to the following information: Ins, myo-inositol; Cho, choline and other trimethylamine metabolites; tCr, creatine and phospho-
creatine; tNAA, N-acetylaspartate and N-acetylaspartylglutamate. Absolute metabolite concentrations are displayed in (C) and (E) and
given in mM. Cho and Ins are framed, indicating that both concentrations were below the normal range. Normal values in the pari-
eto-occipital white matter for children at the age of 2–5 years are the following (given in mM): tNAA ¼ 7.2 5 0.7; tCr ¼ 5.0 5 0.4;
Cho ¼ 1.95 0.2; Ins 3.75 0.6.fetal brain and seems to be the predominant folate trans-
porter during prenatal brain development.
Discussion
The expression of different folate-transporting proteins is
tissue speciﬁc and developmentally regulated. Our results
are consistent with previous investigations that found
the largest amounts of human FRa in the choroid plexus,
substantial amounts in the lung, thyroid, and kidney,
but no FRa expression in the intestine, heart, pancreas,
thymus, cerebrum, cerebellum, spinal cord, spleen, liver,
or muscle.10 Recent studies on folate uptake by rat choroid
plexus epithelial cells suggest that FRa-mediated endocy-
tosis may function in tandem with PCFT-mediated
export.11,25 Thus, folates (MTHF) might be endocytosed
at the basolateral plasma side of the choroid plexus, takenThe Americanover by the PCFT in acidiﬁed endosomes, and ﬁnally exo-
cytosed at the apical CSF side of the choroid plexus. Other
models suggesting that the RFC functions in tandem with
FRa are not supported by our results. However, mRNA
expression is not strictly correlated with protein expres-
sion; hence, our results might not reﬂect the exact amount
of expressed folate transporters. Furthermore, transport
capacity and kinetics of different folate transporters vary
signiﬁcantly and depend on the extracellular folate con-
centration. Lastly, the metabolic and subcellular route of
internalized folates is determined by the type of folate-
transporting proteins involved andmight result in transcy-
tosis of monoglutamyl folate or subcellular accumulation
of polyglutamyl folate metabolites that cannot cross cell
membranes.26
In generalized folate deﬁciency caused by hereditary
folate malabsorption (MIM #229050)17 or severe dietary
folate deﬁciency, hematological and neurologicalJournal of Human Genetics 85, 354–363, September 11, 2009 359
Figure 4. Tissue-Specific mRNA Expression of Known Folate
Transporters
Equal amounts of human cDNAs (from BioChain) were used for
comparison of the tissue-speciﬁc expression of FRa, FRb, FRg,
RFC, and PCFT by real-time PCR. The mRNA values were calcu-
lated as n-fold expression relative to the expression of FRa of cap-
sula interna with the use of the formula 2ˆDCT.37 The house
keeping geneGAPDHwas used as an internal reference for compar-
ison of the expression of different folate transporters for one
speciﬁc tissue. The abbreviations used indicate the following
human brain regions: caps, capsula interna; temp, temporal lobe;
chor, choroid plexus; corp, corpus callosum; cort, cerebral cortex;
hippo, hippocampus; fetal, fetal brain. In addition, mRNA expres-
sion for the following human tissues were determined: liver,
kidney (kidn), and skeletal muscle (s.m.). FRa expression is highest
in the choroid plexus and signiﬁcant in kidney. In contrast, FRb is
detectable in various human brain tissues but highly expressed in
the fetal brain and smooth muscles. FRg expression is low in the
human brain, and the function of FRg is presently unclear. The
PCFT is ubiquitously expressed in the human brain and in other
tissues and is thought to function in concert with FRa and FRb.
The RFC is relatively low expressed in human brain tissues but360 The American Journal of Human Genetics 85, 354–363, Septemsymptoms develop within the ﬁrst months of life and may
lead to death in infancy when untreated. In contrast, our
patients developed symptoms beyond the second year of
life, suggesting that alternative, FRa-independent routes
of cerebral folate delivery must exist during fetal brain
development and in the ﬁrst two years of life. One plau-
sible hypothesis relates to the high expression of FRb in
the fetal brain, which may initially compensate for the
loss of FRa function. It is intriguing that we found an
age-dependent drop in FRb expression in leukocytes
when comparing mRNA transcripts from different individ-
uals 2 years of age and older (Figure S2). We could also
show that FRb is upregulated in the human fetal brain,
but we were unable to acquire adequate human material
to demonstrate the potential postnatal downregulation of
FRb expression in the choroid plexus. The high homology
(70% amino acid identity) between FRa and FRb suggests
that both function in tandem with PCFT and that the
high postnatal FRb expression results in the delayed onset
of symptoms in patients with FRa defects. In addition, our
results suggest that FRb might be important for folate
transport within the brain. In the corresponding mouse
models, folr1/ embryos show severe morphogenetic
abnormalities and die in utero. In contrast, folr2 nullizy-
gous embryos develop normally, have no inherent struc-
tural defects or pathologies, and are able to reproduce
successfully.27 Thus, the biological roles of the murine
and human folate receptors seem to differ from each other.
In this inherited disease of cerebral folate transport deﬁ-
ciency, the deﬁcit of glial choline and myo-inositol de-
tected by in vivo MR spectroscopy prior to folinic acid
therapy represents a pathognomonic metabolic pattern.
The deﬁcit of choline and inositol is consistent with the
disturbed myelination found in our patients. A disturbed
synthesis of myelin lipids can experimentally be induced
in six-week-old rats by dietary folate deﬁciency.28 Other
inherited disorders of folate metabolism, most commonly
methylene-tetrahydrofolate reductase (MTHFR [MIM
#236250]) deﬁciency, are also associated with disturbed
myelination and clinical symptoms such as severe psycho-
motor retardation and epilepsy.29 Studies onmthfr/mice
revealed that folate deﬁciency results in increased choline
consumption via oxidation to betaine to maintain sufﬁ-
cient supply of the methyldonor S-adenosyl-methionine,
and choline oxidase activity is maintained in the brain
even under conditions of choline deprivation.30 The short-
fall of choline leads to a lack of phosphatidylcholine31 and
other membrane phospholipids, such as sphingomyelin
(Figure 5). Phosphatidylcholine, sphingomyelin, and other
methylated phospholipids determine important mem-
brane characteristics and are the major components of
myelin (11.2% phosphatidylcholine, 7.9% sphingomye-
lin32). The lack of methylated membrane phospholipids
detectable in the highest amount in liver tissue. The heights of
the solid bars correspond to the mean values and the slim error
bars to the standard deviations.ber 11, 2009
Figure 5. Brain-Specific Biochemical
Pathways Connecting Folate and Choline
Metabolism
During the conversion of S-adenosyl-
methionine (SAM) to S-adenosyl-homo-
cysteine (SAH), a methyl group (-CH3) is
released. This conversion is the keymethyl
donor for most methylation reactions.
SAM is regenerated by the methylation of
homocysteine to methionine. This reac-
tion is mediated mainly by the methyl-tet-
rahydrofolate (MTHF) to tetrahydrofolate
(THF) conversion. Alternatively, the con-
version of choline to dimethylglycine can
deliver the required methyl group to
regenerate SAM. In the case of folate deﬁ-
ciency, SAM is regenerated mainly by the
choline-oxidation pathway, leading to a
secondary choline deﬁciency. At equilib-
rium, more than 90% of the cellular choline and myo-inositol are anchored in membranes in the form of phosphatidylcholine (PCh)
and phosphatidylinositol (PI). However, choline and inositol can be released from their membrane anchor and supplied to the cyto-
plasmic compartment. Thus, choline deﬁciency can result in reduced membrane content of phosphtidylcholine (PCh) and might
also inﬂuence the amount of other phospholipids, such as phosphatidylinositol (PI). During brain development, in particular during
myelin formation, the choline demand for the synthesis of phosphatidylcholine (PCh) and sphingomyelin (SM) is very high, and
choline deﬁciency ultimately results in disturbed myelination that may affect the amount and composition of myelin. Note that
only free, non-membrane-bound choline (and other trimethylamine compounds, such as phosphocholine and glycerophosphocholine)
and free myo-inositol can be detected by proton MRS (Figures 3C–3E).ultimately results in disturbed myelin formation and
stability. It also has a potential inﬂuence on other
membrane phospholipids, such as phosphatidylinositol,
which is a major source of intracellular myo-inositol. Intra-
cellular myo-inositol is derived from recycling in the phos-
phatidylinositol cycle (Figure 5), synthesized de novo from
glucose-6-phosphate, or taken up from extracellular
ﬂuid.33 There is experimental evidence for two distinct
intracellular myo-inositol pools that show different efﬂux
kinetics and tissue distribution.34,35 One myo-inositol
pool, with fast kinetics, is thought to be associated with
the gray matter and primarily responds to the changes of
plasma osmolyte concentrations, whereas the other pool,
with slow kinetics, might be related to the membrane-
associated myo-inositol fraction within the white
matter. Furthermore, studies with dietary supplementation
of myo-inositol showed a 2.5-fold higher increase in
myo-inositol signal in gray matter than in white matter
of the brain when measured by in vivo MR spectroscopy.36
On the basis of these experimental data, we hypothesize
that the disturbed myelin formation in cerebral folate
transport deﬁciency preferentially affects the membrane-
associated myo-inositol compartment with slow
kinetics and white-matter choline but does not affect
gray-matter choline and myo-inositol. Future studies will
be necessary to prove this hypothesis and further elucidate
the interaction of different brain metabolites in myelin
formation.
The discovery of this brain-speciﬁc folate transport
defect, which we believe has not been previously reported,
gives new insight into the brain-speciﬁc function of folate
and allows the distinction to its noncerebral functions that
are present in systemic folate deﬁciency.The AmericanSupplemental Data
Supplemental Data include two ﬁgures and one table and can be
found with this article online at http://www.cell.com/AJHG.
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